دورية أكاديمية
أعرض في EDS

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.

التفاصيل البيبلوغرافية
العنوان: Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
المؤلفون: Go EJ; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Yang H; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Park W; Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seoburo 2066, Suwon, Gyeonggi, 16419, Republic of Korea., Lee SJ; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Han JH; Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seoburo 2066, Suwon, Gyeonggi, 16419, Republic of Korea., Kong SJ; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Lee WS; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Han DK; Department of Biomedical Science, CHA University, Seongnam, Gyeonggi, 13496, Republic of Korea., Chon HJ; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea., Kim C; Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.; Laboratory of Translational Immuno-Oncology, CHA University School of Medicine, Seongnam, Gyeonggi, 13496, Republic of Korea.
المصدر: Small (Weinheim an der Bergstrasse, Germany) [Small] 2023 Oct; Vol. 19 (43), pp. e2300544. Date of Electronic Publication: 2023 Jun 28.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101235338 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1613-6829 (Electronic) Linking ISSN: 16136810 NLM ISO Abbreviation: Small Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Weinheim, Germany : Wiley-VCH, c2005-
مواضيع طبية MeSH: Liposomes* , Neoplasms*/pathology, Humans ; Tumor Microenvironment ; Endothelial Cells ; Neovascularization, Pathologic/drug therapy ; Immunotherapy
مستخلص: Although stimulator of interferon genes (STING) agonists has shown great promise in preclinical studies, the clinical development of STING agonist therapy is challenged by its limited systemic delivery. Here, positively charged fusogenic liposomes loaded with a STING agonist (PoSTING) are designed for systemic delivery and to preferentially target the tumor microenvironment. When PoSTING is administered intravenously, it selectively targets not only tumor cells but also immune and tumor endothelial cells (ECs). In particular, delivery of STING agonists to tumor ECs normalizes abnormal tumor vasculatures, induces intratumoral STING activation, and elicits robust anti-tumor T cell immunity within the tumor microenvironment. Therefore, PoSTING can be used as a systemic delivery platform to overcome the limitations of using STING agonists in clinical trials.
(© 2023 Wiley-VCH GmbH.)
References: Q. Wu, W. Qian, X. Sun, S. Jiang, J. Hematol. Oncol. 2022, 15, 143.
K. M. Hargadon, C. E. Johnson, C. J. Williams, Int. Immunopharmacol. 2018, 62, 29.
Y. Zhang, Z. Zhang, Cell Mol. Immunol. 2020, 17, 807.
C. Robert, Nat. Commun. 2020, 11, 3801.
S. Bagchi, R. Yuan, E. G. Engleman, Annu. Rev. Pathol. 2021, 16, 223.
P. S. Hegde, D. S. Chen, Immunity 2020, 52, 17.
W. S. Lee, H. Yang, H. J. Chon, C. Kim, Exp. Mol. Med. 2020, 52, 1475.
P. Dobosz, M. Stepien, A. Golke, T. Dzieciatkowski, Int. J. Mol. Sci. 2022, 23, 2847.
X. Zhang, X. C. Bai, Z. J. Chen, Immunity 2020, 53, 43.
R. E. Vatner, E. M. Janssen, Mol. Immunol. 2019, 110, 13.
A. Amouzegar, M. Chelvanambi, J. N. Filderman, W. J. Storkus, J. J. Luke, Cancers (Basel) 2021, 13, 2695.
T. Su, Y. Zhang, K. Valerie, X. Y. Wang, S. Lin, G. Zhu, Theranostics 2019, 9, 7759.
G. N. Barber, Trends Immunol. 2014, 35, 88.
M. Motwani, S. Pesiridis, K. A. Fitzgerald, Nat. Rev. Genet. 2019, 20, 657.
B. A. Flood, E. F. Higgs, S. Li, J. J. Luke, T. F. Gajewski, Immunol Rev 2019, 290, 24.
M. Jiang, P. Chen, L. Wang, W. Li, B. Chen, Y. Liu, H. Wang, S. Zhao, L. Ye, Y. He, C. Zhou, J. Hematol. Oncol. 2020, 13, 81.
L. Motedayen Aval, J. E. Pease, R. Sharma, D. J. Pinato, J Clin Med 2020, 9, 3323.
J. Le Naour, L. Zitvogel, L. Galluzzi, E. Vacchelli, G. Kroemer, Oncoimmunology 2020, 9, 1777624.
K. Luo, N. Li, W. Ye, H. Gao, X. Luo, B. Cheng, Molecules 2022, 27, 4638.
A. S. Doshi, S. Cantin, L. B. Prickett, D. A. Mele, M. Amiji, J. Control. Release 2022, 345, 721.
L. Corrales, L. H. Glickman, S. M. McWhirter, D. B. Kanne, K. E. Sivick, G. E. Katibah, S. R. Woo, E. Lemmens, T. Banda, J. J. Leong, K. Metchette, T. W. Dubensky, T. F. Gajewski, Cell Rep. 2015, 11, 1018.
H. Yang, W. S. Lee, S. J. Kong, C. G. Kim, J. H. Kim, S. K. Chang, S. Kim, G. Kim, H. J. Chon, C. Kim, J. Clin. Invest. 2019, 129, 4350.
Y. Zhu, X. An, X. Zhang, Y. Qiao, T. Zheng, X. Li, Mol Cancer 2019, 18, 152.
E. L. Dane, A. Belessiotis-Richards, C. Backlund, J. Wang, K. Hidaka, L. E. Milling, S. Bhagchandani, M. B. Melo, S. Wu, N. Li, N. Donahue, K. Ni, L. Ma, M. Okaniwa, M. M. Stevens, A. Alexander-Katz, D. J. Irvine, Nat. Mater. 2022, 21, 710.
Q. Zhou, Y. Zhou, T. Li, Z. Ge, Macromol. Biosci. 2021, 21, 2100133.
M. Wehbe, L. Wang-Bishop, K. W. Becker, D. Shae, J. J. Baljon, X. He, P. Christov, K. L. Boyd, J. M. Balko, J. T. Wilson, J. Control. Release 2021, 330, 1118.
X. Sun, Y. Zhang, J. Li, K. S. Park, K. Han, X. Zhou, Y. Xu, J. Nam, J. Xu, X. Shi, L. Wei, Y. L. Lei, J. J. Moon, Nat. Nanotechnol. 2021, 16, 1260.
H. Kong, K. Yi, C. Zheng, Y. H. Lao, H. Zhou, H. F. Chan, H. Wang, Y. Tao, M. Li, J. Mater. Chem. B 2022, 10, 6841.
B. Kim, H. B. Pang, J. Kang, J. H. Park, E. Ruoslahti, M. J. Sailor, Nat. Commun. 2018, 9, 1969.
S. Kube, N. Hersch, E. Naumovska, T. Gensch, J. Hendriks, A. Franzen, L. Landvogt, J. P. Siebrasse, U. Kubitscheck, B. Hoffmann, R. Merkel, A. Csiszar, Langmuir 2017, 33, 1051.
K. Pombo Garcia, K. Zarschler, L. Barbaro, J. A. Barreto, W. O'Malley, L. Spiccia, H. Stephan, B. Graham, Small 2014, 10, 2516.
H. H. Gustafson, D. Holt-Casper, D. W. Grainger, H. Ghandehari, Nanotoday 2015, 10, 487.
M. Chen, J. G. Geng, Arch. Immunol. Ther. Exp. 2006, 54, 75.
J. G. Geng, M. Chen, K. C. Chou, Curr. Med. Chem. 2004, 11, 2153.
H. Kobayashi, K. C. Boelte, P. C. Lin, Curr. Med. Chem. 2007, 14, 377.
C. Kim, H. Yang, Y. Fukushima, P. E. Saw, J. Lee, J. S. Park, I. Park, J. Jung, H. Kataoka, D. Lee, W. D. Heo, I. Kim, S. Jon, R. H. Adams, S. Nishikawa, A. Uemura, G. Y. Koh, Cancer Cell 2014, 25, 102.
J. S. Park, I. K. Kim, S. Han, I. Park, C. Kim, J. Bae, S. J. Oh, S. Lee, J. H. Kim, D. C. Woo, Y. He, H. G. Augustin, I. Kim, D. Lee, G. Y. Koh, Cancer Cell 2016, 30, 953.
D. Hanahan, R. A. Weinberg, Cell 2011, 144, 646.
S. J. Lee, H. Yang, W. R. Kim, Y. S. Lee, W. S. Lee, S. J. Kong, H. J. Lee, J. H. Kim, J. Cheon, B. Kang, H. J. Chon, C. Kim, J. Immunother. Cancer 2021, 9, e002195.
T. He, Z. Hao, M. Lin, Z. Xin, Y. Chen, W. Ouyang, Q. Yang, X. Chen, H. Zhou, W. Zhang, P. Wu, F. Xu, Oncoimmunology 2022, 11, 2093054.
M. E. Eichhorn, I. Ischenko, S. Luedemann, S. Strieth, A. Papyan, A. Werner, H. Bohnenkamp, E. Guenzi, G. Preissler, U. Michaelis, K. W. Jauch, C. J. Bruns, M. Dellian, Int. J. Cancer 2010, 126, 1235.
A. S. Abu Lila, T. Ishida, H. Kiwada, Pharm. Res. 2010, 27, 1171.
A. Awada, I. N. Bondarenko, J. Bonneterre, E. Nowara, J. M. Ferrero, A. V. Bakshi, C. Wilke, M. Piccart, C. Ts. group, Ann. Oncol. 2014, 25, 824.
J. M. Lohr, S. L. Haas, W. O. Bechstein, G. Bodoky, K. Cwiertka, W. Fischbach, U. R. Folsch, D. Jager, D. Osinsky, J. Prausova, W. E. Schmidt, M. P. Lutz, C. T. S. Group, Ann. Oncol. 2012, 23, 1214.
M. E. Eichhorn, S. Strieth, S. Krasnici, B. Sauer, M. Teifel, U. Michaelis, K. Naujoks, M. Dellian, Angiogenesis 2004, 7, 133.
G. Thurston, J. W. McLean, M. Rizen, P. Baluk, A. Haskell, T. J. Murphy, D. Hanahan, D. M. McDonald, J. Clin. Invest. 1998, 101, 1401.
M. Schmitt-Sody, S. Strieth, S. Krasnici, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, M. Dellian, Clin. Cancer Res. 2003, 9, 2335.
M. E. Eichhorn, S. Luedemann, S. Strieth, A. Papyan, H. Ruhstorfer, H. Haas, U. Michaelis, B. Sauer, M. Teifel, G. Enders, G. Brix, K.-W. Jauch, C. J. Bruns, M. Dellian, Cancer Biol. Ther. 2007, 6, 920.
G. Caracciolo, D. Pozzi, A. L. Capriotti, C. Cavaliere, A. Lagana, J. Nanopart. Res. 2013, 15, 1498.
I. San-Millán, G. A. Brooks, Carcinogenesis 2017, 38, 119.
B. Chen, W. Le, Y. Wang, Z. Li, D. Wang, L. Ren, L. Lin, S. Cui, J. Hu, Y. Hu, P. Yang, R. C. Ewing, D. Shi, Z. Cui, Theranostics 2016, 6, 1887.
C. Liu, L. Zhang, W. Zhu, R. Guo, H. Sun, X. Chen, N. Deng, Mol. Ther. Methods Clin. Dev. 2020, 18, 751.
S. Krasnici, A. Werner, M. E. Eichhorn, M. Schmitt-Sody, S. A. Pahernik, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, K. Naujoks, M. Dellian, Int. J. Cancer 2003, 105, 561.
S. Ran, A. Downes, P. E. Thorpe, Cancer Res. 2002, 62, 6132.
S. Strieth, M. E. Eichhorn, A. Werner, B. Sauer, M. Teifel, U. Michaelis, A. Berghaus, M. Dellian, Clin. Cancer Res. 2008, 14, 4603.
J. Hyung, E. J. Cho, J. Kim, J. H. Kim, J. E. Kim, Y. S. Hong, T. W. Kim, C. O. Sung, S. Y. Kim, Cancer Res Treat. 2022, 54, 1175.
فهرسة مساهمة: Keywords: Immunotherapy; positively charged liposomes; stimulator of interferon genes (STING); systemic delivery; tumor angiogenesis; vascular normalization
المشرفين على المادة: 0 (Liposomes)
تواريخ الأحداث: Date Created: 20230629 Date Completed: 20231026 Latest Revision: 20231026
رمز التحديث: 20231027
DOI: 10.1002/smll.202300544
PMID: 37381624
قاعدة البيانات: MEDLINE
الوصف
تدمد:1613-6829
DOI:10.1002/smll.202300544